Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Obesity

Type 2 diabetes drug aids weight loss, study finds

Patients given GLP-1 receptor agonists to treat obesity lost weight compared with those treated with placebo.

GLP-1 receptor agonists, diabetes drug injectors

Source: Dr P Marazzi / Science Photo Library

Researchers evaluated the use of semaglutide (SEMA) for the treatment of obesity in a dose-ranging study (doses: 0.05mg, 0.1mg, 0.2mg, 0.3mg or 0.4mg) versus placebo and an active liraglutide (LIRA) control, each combined with counselling

Up to 80% of those treated with GLP-1 receptor agonists lose weight, according to a randomised, placebo-controlled study in 957 individuals without diabetes.

Researchers evaluated the use of semaglutide (SEMA) for the treatment of obesity in a dose-ranging study (doses: 0.05mg, 0.1mg, 0.2mg, 0.3mg or 0.4mg) versus placebo and an active liraglutide (LIRA) control, each combined with counselling[1].

After one year, estimated mean weight loss was –2.3% in the placebo group and –7.8% in the LIRA group. In the SEMA treatment group, weight loss ranged from –6% at 0.05mg to –13.8% at 0.4mg.

An estimated 23% of participants lost weight in the placebo group compared with 66% in the LIRA group. In the SEMA group, it ranged from 54% of subjects in the 0.05mg group to 83% in the 0.4mg group.

Presenting their findings at the Endocrine Society’s 100th annual meeting in Chicago (18 March 2018), the researchers concluded that, combined with counselling, SEMA was well tolerated and led to higher weight loss than placebo in obese people without diabetes.

Citation: Clinical Pharmacist DOI: 10.1211/CP.2018.20205053

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • GLP-1 receptor agonists, diabetes drug injectors

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.